Opinion

Now that the US medicines regulator has granted accelerated approval for the Alzheimer’s drug lecanemab, the way is clear for similar approvals in the UK and Europe.  We have been here before, of course, when the American Food and Drug Administration gave qualified approval two years ago to another monoclonal antibody drug called aducanumab, which…...

By Keith Oliver The start of the New Year is an ideal time to revisit or reconsider what has gone before and what might lie ahead. It seems quite unbelievable that 12 years ago, when I was diagnosed with Alzheimer’s disease, I could not find any books written by or with a person with dementia…....

Diagnosis rates are down, care providers are closing, and waiting lists for social care needs assessments are growing. What will it take to rebuild dementia care? George Rook, a Dementia Diarist living in north Shropshire: “Rebuild” implies that there was previously a structure that collapsed. But there has been no such structure, universally in place…...

This is something of a departure from our usual Dementia Diaries column. At the end of 2022 we held a week-long festival as a culmination of DEEP’s 10th Anniversary. It comes as no surprise that Diarists popped up regularly across the 21 events that we organised over the week. Dementia Diarists have their own virtual…...